|
1
|
Poston GJ, Figueras J, Giuliante F, et al:
Urgent need for a new staging system in advanced colorectal cancer.
J Clin Oncol. 26:4828–4833. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saltz LB, Meropol NJ, Loehrer PJ Sr,
Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in
patients with refractory colorectal cancer that expresses the
epidermal growth factor receptor. J Clin Oncol. 22:1201–1208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab mono-therapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
51:337–345. 2004. View Article : Google Scholar
|
|
4
|
Chung KY, Shia J, Kemeny NE, et al:
Cetuximab shows activity in colorectal cancer patients with tumors
that do not express the epidermal growth factor receptor by
immunohistochemistry. J Clin Oncol. 23:1803–1810. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jonker DJ, O’Callaghan CJ, Karapetis CS,
et al: Cetuximab for the treatment of colorectal cancer. N Engl J
Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sobrero AF, Maurel J, Fehrenbacher L, et
al: EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Camp ER, Summy J, Bauer TW, Liu W, Gallick
GE and Ellis LM: Molecular mechanisms of resistance to therapies
targeting the epidermal growth factor receptor. Clin Cancer Res.
11:397–405. 2005.PubMed/NCBI
|
|
8
|
Siena S, Sartore-Bianchi A, Di
Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting
clinical outcome of epidermal growth factor receptor-targeted
therapy in metastatic colorectal cancer. J Natl Cancer Inst.
101:1308–1324. 2009. View Article : Google Scholar
|
|
9
|
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ,
Kussie P and Ferguson KM: Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van Cutsem E, Kohne CH, Hitre E, et al:
Cetuximab and chemo-therapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
11
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lièvre A, Bachet JB, Boige V, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008.
|
|
14
|
Di Fiore F, Blanchard F, Charbonnier F, et
al: Clinical relevance of KRAS mutation detection in metastatic
colorectal cancer treated by Cetuximab plus chemotherapy. Br J
Cancer. 96:1166–1169. 2007.PubMed/NCBI
|
|
15
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cappuzzo F, Finocchiaro G, Rossi E, et al:
EGFR FISH assay predicts for response to cetuximab in chemotherapy
refractory colorectal cancer patients. Ann Oncol. 19:717–723. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Personeni N, Fieuws S, Piessevaux H, et
al: Clinical usefulness of EGFR gene copy number as a predictive
marker in colorectal cancer patients treated with cetuximab: a
fluorescent in situ hybridization study. Clin Cancer Res.
14:5869–5876. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frattini M, Saletti P, Romagnani E, et al:
PTEN loss of expression predicts cetuximab efficacy in metastatic
colorectal cancer patients. Br J Cancer. 97:1139–1145. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khambata-Ford S, Garrett CR, Meropol NJ,
et al: Expression of epiregulin and amphiregulin and K-ras mutation
status predict disease control in metastatic colorectal cancer
patients treated with cetuximab. J Clin Oncol. 25:3230–3237. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Gordon M, Schultheis AM, et al:
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of
epidermal growth factor receptor expressing metastatic colorectal
cancer patients treated with single-agent cetuximab. J Clin Oncol.
25:3712–3718. 2007. View Article : Google Scholar
|
|
21
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, et al: Oncogenic activation of the RAS/RAF
signaling pathway impairs the response of metastatic colorectal
cancers to anti-epidermal growth factor receptor antibody
therapies. Cancer Res. 67:2643–2648. 2007. View Article : Google Scholar
|
|
22
|
Di Nicolantonio F, Martini M, Molinari F,
et al: Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol.
26:5705–5712. 2008.
|
|
23
|
Sartore-Bianchi A, Martini M, Molinari F,
et al: PIK3CA mutations in colorectal cancer are associated with
clinical resistance to EGFR-targeted monoclonal antibodies. Cancer
Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA
mutation/PTEN expression status predicts response of colon cancer
cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar
|
|
25
|
Perrone F, Lampis A, Orsenigo M, et al:
PI3KCA/PTEN deregulation contributes to impaired responses to
cetuximab in metastatic colorectal cancer patients. Ann Oncol.
20:84–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loupakis F, Pollina L, Stasi I, et al:
PTEN expression and KRAS mutations on primary tumors and metastases
in the prediction of benefit from cetuximab plus irinotecan for
patients with meta-static colorectal cancer. J Clin Oncol.
27:2622–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oden-Gangloff A, Di Fiore F, Bibeau F, et
al: TP53 mutations predict disease control in metastatic colorectal
cancer treated with cetuximab-based chemotherapy. Br J Cancer.
100:1330–1335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Debucquoy A, Haustermans K, Daemen A, et
al: Molecular response to cetuximab and efficacy of preoperative
cetuximab-based chemoradiation in rectal cancer. J Clin Oncol.
27:2751–2757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Black PC, Brown GA, Inamoto T, et al:
Sensitivity to epidermal growth factor receptor inhibitor requires
E-cadherin expression in urothelial carcinoma cells. Clin Cancer
Res. 14:1478–1486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yashiro M, Carethers JM, Laghi L, et al:
Genetic pathways in the evolution of morphologically distinct
colorectal neoplasms. Cancer Res. 61:2676–2683. 2001.PubMed/NCBI
|
|
31
|
Lenz HJ, Danenberg KD, Leichman CG, et al:
p53 and thymidylate synthase expression in untreated stage II colon
cancer: associations with recurrence, survival, and site. Clin
Cancer Res. 4:1227–1234. 1998.PubMed/NCBI
|
|
32
|
Allegra CJ, Paik S, Colangelo LH, et al:
Prognostic value of thymidylate synthase, Ki-67, and p53 in
patients with Dukes’ B and C colon cancer: a National Cancer
Institute-National Surgical Adjuvant Breast and Bowel Project
collaborative study. J Clin Oncol. 21:241–250. 2003.
|
|
33
|
Jakob C, Liersch T, Meyer W, Becker H,
Baretton GB and Aust DE: Predictive value of Ki67 and p53 in
locally advanced rectal cancer: correlation with thymidylate
synthase and histo-pathological tumor regression after neoadjuvant
5-FU-based chemoradiotherapy. World J Gastroenterol. 14:1060–1066.
2008. View Article : Google Scholar
|
|
34
|
El-Serafi MM, Bahnassy AA, Ali NM, et al:
The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72
mutations in Egyptian patients with stage II colorectal cancer.
Cancer. 116:4954–4964. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Triest B, Pinedo HM, Blaauwgeers JL,
et al: Prognostic role of thymidylate synthase, thymidine
phosphorylase/platelet-derived endothelial cell growth factor, and
proliferation markers in colorectal cancer. Clin Cancer Res.
6:1063–1072. 2000.
|
|
36
|
Dorudi S, Sheffield JP, Poulsom R,
Northover JM and Hart IR: E-cadherin expression in colorectal
cancer. An immunocytochemical and in situ hybridization study Am J
Pathol. 142:981–986. 1993.PubMed/NCBI
|
|
37
|
Lugli A, Zlobec I, Minoo P, et al:
Prognostic significance of the wnt signalling pathway molecules
APC, beta-catenin and E-cadherin in colorectal cancer: a tissue
microarray-based analysis. Histopathology. 50:453–464. 2007.
View Article : Google Scholar
|
|
38
|
Pece S, Chiariello M, Murga C and Gutkind
JS: Activation of the protein kinase Akt/PKB by the formation of
E-cadherin-mediated cell-cell junctions. Evidence for the
association of phosphatidylinositol 3-kinase with the E-cadherin
adhesion complex. J Biol Chem. 274:19347–19351. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pece S and Gutkind JS: Signaling from
E-cadherins to the MAPK pathway by the recruitment and activation
of epidermal growth factor receptors upon cell-cell contact
formation. J Biol Chem. 275:41227–41233. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fedor-Chaiken M, Hein PW, Stewart JC,
Brackenbury R and Kinch MS: E-cadherin binding modulates EGF
receptor activation. Cell Commun Adhes. 10:105–118. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Witta SE, Gemmill RM, Hirsch FR, et al:
Restoring E-cadherin expression increases sensitivity to epidermal
growth factor receptor inhibitors in lung cancer cell lines. Cancer
Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
44
|
De Roock W, Piessevaux H, De Schutter J,
et al: KRAS wild-type state predicts survival and is associated to
early radiological response in metastatic colorectal cancer treated
with cetuximab. Ann Oncol. 19:508–515. 2008.PubMed/NCBI
|
|
45
|
Noske A, Lipka S, Budczies J, et al:
Combination of p53 expression and p21 loss has an independent
prognostic impact on sporadic colorectal cancer. Oncol Rep. 22:3–9.
2009.PubMed/NCBI
|
|
46
|
Saleh HA, Jackson H, Khatib G and Banerjee
M: Correlation of bcl-2 oncoprotein immunohistochemical expression
with proliferation index and histopathologic parameters in
colorectal neoplasia. Pathol Oncol Res. 5:273–279. 1999. View Article : Google Scholar
|
